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Abstract
Background: The 23-valent polysaccharide pneumococcal vaccine (PPV) is currently recommended in elderly and
high-risk adults. However, its efficacy in preventing pneumococcal infections remains controversial. This study
assessed the clinical effectiveness of vaccination against invasive pneumococcal disease (IPD) among people over
60 years.
Methods: Population-based case-control study that included 88 case patients over 60 years-old with a laboratory-
confirmed IPD (bacteraemic pneumonia, meningitis or sepsis) and 176 outpatient control subjects who were
matched by primary care centre, age, sex and risk stratum. Adjusted odds ratios (ORs) for vaccination were
calculated using conditional logistic regression, controlling for underlying conditions. Vaccine effectiveness was
estimated as (1 - OR) ×100.
Results: Pneumococcal vaccination rate was significantly lower in cases than in control subjects (38.6% vs 59.1%;
p = 0.002). The adjusted vaccine effectiveness was 72% (OR: 0.28; 95% CI: 0.15-0.54) against all IPD and 77%
(OR: 0.23; 95% CI: 0.08-0.60) against vaccine-type IPD. Vaccination was significantly effective against all IPD in both
age groups: 60-79 years-old (OR 0.32; 95% CI: 0.14-0.74) and people 80 years or older (OR: 0.29; 95% CI: 0.09-0.91).
Vaccination appears significantly effective as for high-risk immunocompetent subjects (OR: 0.29; 95% CI: 0.11-0.79)
as well as for immunocompromised subjects (OR: 0.12; 95% CI: 0.03-0.53).
Conclusion: These findings confirm the effectiveness of the 23-valent PPV against IPD, and they also support the
benefit of vaccination in preventing invasive infections among high-risk and older people.
Background
Streptococcus pneumoniae is an important cause of mor-
bidity and mortality worldwide, particularly in young
children and elderly individuals, who are more suscepti-
ble to infection. The main reservoir of the microorgan-
isms is the nasopharynx, and pneumococcal disease
presentation depends on whether the bacteria spread to
adjacent mucosal tissues causing mucosal infections (oti-
tis, sinusitis, bronchitis and nonbacteremic pneumonias)
or whether it invades the bloodstream, or other sterile
sites, resulting in invasive pneumococcal disease (IPD),
principally bacteraemic pneumonias, meningitis and sep-
sis[1].
For many years, control of pneumococcal infections
was largely focused on case identification and antimicro-
bial treatment. Although these actions reduce the conse-
quences of disease, they have little impact on the overall
disease burden and have contributed to the increasing
rates of antimicrobial resistance among S. pneumoniae
strains. The need for preventive strategies with a broad
public health impact has been recognized for several
decades and the aim of finding an effective anti- * Correspondence: oochoa.tarte.ics@gencat.cat
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this time[2,3].
The existence of more than 90 distinct serotypes (dif-
fering in their chemical compositions, potential immu-
nogenicity and epidemiological impact on different
population groups) has largely complicated the develop-
ment and evaluation of anti-pneumococcal vaccines[4].
To date, only a 23-valent polysaccharide pneumococcal
vaccine (PPV) for use in adults and a 7-valent conjugate
pneumococcal vaccine (CPV) for use in infants are avail-
able in clinical practice, although two new CPVs
(including 10 and 13 serotypes) will also be available
shortly.
The currently available 23-valent PPV was licensed in
1983 and it is usually recommended for use in high-risk
adults and elderly people. The vaccine contains capsular
polysaccharide antigens from the 23 most dominant ser-
otypes among clinical isolates of S. pneumoniae,
accounting for approximately 90% of overall invasive
infections in the adult population[5,6].
If we consider IPD, the most specific and severe mani-
festation of the pneumococcal infection, its incidence is
low (approximately 10-20 cases per 100,000 all-age inha-
bitants)[1] and prospective randomized controlled trials
(RCTs) generally failed to demonstrate a significant pro-
tective effect of PPV against this outcome. In contrast,
several case-control and indirect cohort studies have
found considerable effectiveness against IPD or pneu-
mococcal bacteraemia. Several meta-analyses have pro-
duced varied results depending on which trials were
included, but have generally concluded that PPV would
be considerably effective in preventing IPD among
immunocompetent adults [7-16]. In the last published
meta-analysis, which includes only RCTs, Huss et al
[17] have reported that trial quality explains a substan-
tial proportion of the heterogeneity in the results of
meta-analyses. They conclude that there is no evidence
of vaccine protection in trials of higher methodological
quality and suggest that PPV could be not efficacious
against either IPD or pneumonia[17].
In Catalonia, a region in the northeast of Spain with a
population of six million people, a publicly funded anti-
pneumococcal vaccination program for high-risk adults
and people over 65 years began in October 1999.
Further, the vaccination program was extended for all
individuals 60 years or older (with or without high-risk
conditions) in 2002. Since then, a free 23-valent PPV is
offered when the patients come to the Primary Health
Care Centers (PHCCs) during the annual influenza vac-
cination campaigns or in any other visit throughout the
year[18]. In order to evaluate the effectiveness of the
antipneumococcal vaccination program, we performed a
population-based case-control study among people over
50 years in our study area. The results of vaccine
effectiveness against pneumonia (with or without bacter-
aemia) have been published[19]. In the present study we
have evaluated the clinical effectiveness of the 23-valent
PPV against IPD (bacteremic pneumonia, meningitis or
sepsis) in the population subgroup 60 years or older,
and according to the age and the risk strata of the
patients.
Methods
Design, setting and study population
Population-based case-control study that included
88 patients aged 60 years or more with laboratory-
confirmed invasive pneumococcal disease and 176 con-
trol subjects. The study was carried out in three districts
(Tarragones, Alt Camp, Baix Penedes) belonging to the
Health Region of Tarragona (a mixed residential-indus-
trial region in the Mediterranean coast of Catalonia,
Spain).
Case patients were identified from an active surveil-
lance made in the participating PHCCs and Laboratory
Departments of 3 reference hospitals in the study area
(Joan XXIII, Santa Tecla and Pius Hospitals) from Janu-
ary 2002 to April 2007. The study was approved by the
ethical committee of the Catalonian Health Institute
(ID: FIS PS-050231) and was conducted in accordance
with the general principles for observational studies.
Data sources
The hospital discharge diagnoses databases, coded
according to the International Classification of Diseases,
9th Revision, Clinical modification (ICD-9), were initially
used to identify possible case patients. The institutional
medical databases of each PHCC (which contain admin-
istrative data together with registries of medication pre-
scriptions, medical conditions and chronic diseases
associated with ICD-9 codes) were used to select poten-
tial control subjects in each participating PHCC. Pri-
mary care clinical records were used to investigate the
vaccination status of case and control subjects, and they
were also used to identify the presence of underlying
conditions registered before the date of matching.
Case patients
A case was defined as a patient aged 60 years or older,
living in the study area, who had a laboratory-confirmed
episode of IPD during the study period. IPD was defined
as a patient from whom S. pneumoniae was obtained by
culture of blood samples, CSF samples, or other nor-
mally sterile sites. IPD cases were identified on the basis
of ICD-9 discharge codes for bacteremia (038.0, 038.2,
041.0, 041.2), meningitis (320.1) or pneumonia (481).
Laboratory records were also used for identified cases of
pneumococcal infections not detected in ICD-9 dis-
charge codes.
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record with the use of standardized data-collection
instrument. IPD case was considered if, on conclusion
of the medical record review, the physician reviewer ver-
ified this diagnosis and it was not a readmission or
another diagnosis.
Control subjects
For each case patient, two control subjects were selected
from the participating PHCCs. Control subjects were
matched to their respective case patient by PHCC, age
(birthday within +/- 3 years of the case patient’sb i r t h -
day), sex, and main chronic medical condition (using
risk stratum which are defined below).
To identify appropriate control subjects, we performed
searches of the computerized medical record system at
each PHCC to obtain lists of potential control patients
according to ICD-9 codes for every underlying condi-
tion, and then we randomly selected 2 control subjects
from the list of potential control patients with the
appropriate conditions. If the list of potential control
subjects for a case patient had less than 2 persons, then
we systematically expanded the criteria (firstly, for age
until +/- 10 years; secondly, searching for adequate con-
trol subjects in the nearest PHCC.
Risk strata
To ensure that matching was adequate, underlying med-
ical conditions of the case patients were grouped into 3
risk strata on the basis of the degree of immunocompro-
mise and risk for pneumococcal disease. Stratum 1
included persons with conditions associated with possi-
ble immunocompromise: immunodeficiency (including
AIDS), asplenia, cancer (solid organ or haematological
neoplasia), chronic nephropathy (nephrotic syndrome,
renal failure, dialysis or transplantation), and long-term
corticosteroid therapy (20 mg/day of prednisone or
equivalent). Stratum 2 included patients without a level
1 condition but who had a history of chronic lung dis-
ease (chronic bronchitis, emphysema or asthma), liver
disease (cirrhosis or alcoholic hepatitis), heart disease
(congestive heart failure or chronic angina) and diabetes
mellitus. Stratum 3 included patients without level 1 or
level 2 conditions.
When a case was categorized as risk stratum 1, it was
matched with two control patients who had disease or
condition in risk stratum 1. When a case patient had one
underlying condition and was categorized as risk stratum
2, control subjects were selected with the same medical
condition. If a case patient had multiple underlying con-
ditions, control patients were matched according to the
first-listed condition above. If the case patient was risk
stratum 3, then the control subjects were only matched
according to their smoking or non smoking status.
Vaccination history
Vaccination status of case and control subjects were
determined by a review of the PHCCs’ clinical records,
which contain specially designated fields for pneumo-
coccal and influenza vaccinations. We assumed that
information in clinical records was complete, so a sub-
ject was considered as unvaccinated when a vaccination
was not recorded.
Patients and their respective matched control subjects
were considered as vaccinated against pneumococcus if
the 23-valent PPV had been administered at least 14
days before the onset of the illness for the case patient.
Similarly, influenza vaccination status was determined
according to whether the subjects had received the flu
vaccine in the autumn prior to the IPD date. The inves-
tigators who performed microbiological procedures and
those who selected control subjects were unaware of the
vaccination histories of the subjects.
Case-control analysis
The differences between case and control groups were
evaluated with the chi-squared or Students’ test as
appropriate. The crude association between the out-
comes and vaccination was evaluated using the Mantel-
Haenszel matched odds ratio (OR). Conditional logistic
regression was used to calculate the adjusted matched
ORs. In the initial regression models, we adjusted for:
age, sex, lung disease, heart disease, stroke, diabetes,
liver disease, renal disease, cancer, corticosteroid ther-
apy, alcoholism, smoking and influenza vaccine status.
To avoid potential residual confusion due to the use of
age as a categorical variable, all the models have been
adjusted for age as continuous.
We performed stratified analysis in cases occurred
within influenza period (January-April) or non-influenza
period (May-December), in two age groups (60-79 yrs,
80 yrs or more) and in each of the three risk strata. We
checked for confounding factors, interactions and coli-
nearity among the independent variables. All the models
have been compared through the partial likelihood ratio
test or the Akaike’s information criterion (AIC). We
evaluated the assessment of fit in the final models[20].
Vaccine effectiveness was calculated by (1-matched OR)
×100%. Statistical significance was set at p < 0.05 (two-
tailed). The analyses were performed using Stata/SE
Version 9.1. (Stata Corp.)
Results
Characteristics of the study population
Among the total 88 cases, eight (9.1%) were meningitis,
four (4.5%) were bacteraemia with no apparent focus
and 76 (86.4%) were bacteraemic pneumococcal pneu-
monias. Five cases of bacteremic pneumonia were mana-
ged as outpatient whereas the remaining 83 case
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sion to the intensive care unit). Overall case-fatality rate
reached 18.2% (16/88).
Of the 53 identified serotypes, 44 (83%) were vaccine
types, 4 (7.6%) were vaccine-related serotypes and 5
(9.4%) were non-vaccine serotypes. Of the remaining 35
isolates, 9 were not typable and 26 were not typed.
Table 1 shows absolute numbers and proportions of the
different identified serotypes.
Mean age of case patients was 73.2 years (SD: 10.8)
and age of case patients ranged between 60-92 years.
Overall, 54 cases (61.4%) were male and 37 (42.1%) were
80 years or older. Twenty-nine cases (32.9%) were
assigned to risk stratum 1, 41 (46.6%) to risk stratum 2,
and 18 (20.5%) to risk stratum 3.
The characteristics of the cases and control subjects
are summarized in table 2. The pneumococcal vaccina-
tion rate was significantly lower in cases than in control
subjects (38.6% vs 59.1%; p = 0.002). As for the other
characteristics the two groups were essentially similar,
except for a slightly more significant prevalence of
stroke among case patients than in control subjects
(11.4% vs 5.1%, p = 0.064) and a lower influenza
vaccination rate in case patients than in control subjects
(48.3% vs 64.8%, p = 0.010).
Effectiveness of the vaccination
In the crude analysis, vaccine effectiveness was 66%
(95% CI: 37-82) against all IPD cases and it was 72%
(95% CI: 33-89) against infections due to vaccine-types.
In the multivariable analysis, the values of different
results on the adjusted vaccine effectiveness were very
similar to those observed in the crude analysis, obser-
ving that the adjusted vaccine effectiveness was 72%
(95% CI: 46-85) against all IPD and 77% (95% CI: 40-
92) against vaccine-type IPD. Table 3 shows vaccina-
tion histories in cases and control subjects, unadjusted
and adjusted Odds Ratios, and estimates of effective-
ness of the vaccination against vaccine-type IPD and
all IPD.
During the study period, 50 cases occurred within
influenza period and 38 cases occurred within nonin-
fluenza period. Within influenza period, the adjusted
vaccine effectiveness was 73% (95% CI: 15-92) against all
IPD, whereas it was 63% (95% CI:8-85) within nonin-
fluenza period. Table 4 shows vaccination histories in
cases and control subjects, unadjusted and adjusted
Odds Ratios, and estimates of effectiveness of the vacci-
nation against all IPD according to influenza and nonin-
fluenza periods.
In stratified analysis according to age subgroups, vac-
cination appears significantly effective against all IPD in
both age groups 60-79 years (adjusted OR: 0.32; 95% CI:
0.14-0.74) and 80 years or older (adjusted OR: 0.29; 95%
CI 0.09-0.91).
According to the risk strata of the patients, the recep-
tion of the 23-valent PPV was associated with a lower
risk of all IPD for vaccinated subjects in the three risk
strata, but vaccination effectiveness only reached statisti-
cal significance in risk stratum 1 (adjusted OR: 0.12;
95% CI: 0.03-0.53) and risk stratum 2 (adjusted OR:
0.29; 95% CI: 0.11-0.79).
Table 5 shows vaccination histories in case and con-
trol subjects, unadjusted and adjusted analysis of vacci-
nation effectiveness against IPD according to age and
risk strata of the patients.
Discussion
The effectiveness of PPV is controversial. Despite
numerous studies, contradictory results have been
reported and several meta-analyses have been inconclu-
sive to date. Excluding earlier trials in younger adults,
[21,22] prospective RCTs have failed to demonstrate a
significant protective effect of the vaccination. However,
several case-control and cohort studies have reported a
considerable protective effect (ranging between 40-80%)
in preventing IPD in different populations [23-28].
Table 1 Absolute numbers and proportions of the
different pneumococcal serotypes, according to they
were included or not in the 23-valent polysaccharide
pneumococcal vaccine (PPV) identified among case
patients (n = 53).
S. pneumonia serotype N (%)
Serotypes included in 23-valent PPV
1 6 (11.3)
3 7 (13.2)
4 3 (5.6)
5 2 (3.8)
6B 3 (5.6)
7F 3 (5.6)
8 4 (7.5)
9V 2 (3.8)
12F 1 (1.9)
14 8 (15.1)
15B 1 (1.9)
19A 2 (3.8)
19F 2 (3.8)
Vaccine-related serotypes
6A 2 (3.8)
23A 2 (3.8)
Non-vaccine serotypes
13 1 (1.9)
16 1 (1.9)
31 2 (3.8)
38 1 (1.9)
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did not prove any significant protective effect whereas
those meta-analyses which also included observational
studies in their analysis concluded that PPV could be
considerably effective in preventing IPD (although its
efficacy could be low or null among immunocompro-
mised, high-risk and older adults) [7-17].
In the present study, a significant adjusted vaccine
effectiveness of 72% (46-85) against overall IPD has
been found. The effect of the vaccine in preventing vac-
cine-type IPD was greater, with an estimated effective-
ness of 77% (40-92).
In our study, vaccination was significantly effective as
for people 60-79 years as well as for older people 80
years or more. In addition, vaccination appears signifi-
cantly effective for high-risk people and subjects with
possible immunocompromise. Our findings fit with a
prior case control study that showed an effectiveness of
Table 2 Characteristics of subjects by case-control status (88 matched sets) to evaluate the clinical effectiveness of the
23-valent polysaccharide pneumococcal vaccine in preventing Invasive pneumococcal disease among Spanish people
60 years or older.
Characteristic Cases
(n = 88)
Controls
a
(n = 176)
P-value
b
Age (yrs), mean (SD) 73.2 (10.8) 72.8 (10.2) 0.612
Sex male 54 (61.4) 108 (61.4) 1.000
Cancer 12 (13.6) 32 (18.2) 0.350
Chronic renal disease 15 (17.0) 25 (14.2) 0.865
Corticosteroid therapy 4 (4.5) 10 (5.7) 0.698
Chronic lung disease 19 (21.6) 44 (25.0) 0.540
Chronic liver disease 7 (8.0) 16 (9.1) 0.758
Chronic heart disease 31 (35.2) 46 (26.1) 0.126
Diabetes mellitus 21 (23.9) 51 (29) 0.379
Stroke 10 (11.4) 9 (5.1) 0.064
Alcoholism 5 (5.7) 8 (4.3) 0.687
Smoking 18 (20.5) 27 (15.3) 0.298
History of pneumococcal vaccination 34 (38.6) 104 (59.1) 0.002
History of influenza vaccination in autumn prior to the event 42 (48.3) 114 (64.8) 0.010
NOTE: Data are numbers (percentage) of subjects, unless otherwise indicated. SD, standard deviation.
aCriteria for matching control subjects with case patients were extended in 9 sets for age (4-5 years in 3 sets, 6-7 years in 2 sets, and 8-10 years in 4 sets), and it
was extended for nearest municipality or Primary Health Care Center in 14 sets.
b P-values were calculated with the chi-squared test and Student’s test, as appropriate.
Table 3 Vaccination histories in cases and control subjects, unadjusted and adjusted Odds Ratios, and estimates of
effectiveness of pneumococcal vaccination against overall invasive pneumococcal disease (IPD) and IPD by vaccine
types.
Unadjusted analysis Adjusted analysis
Type of infection No. of subjects No. (%) of vaccinated OR
a (95% CI) Effectiveness of
vaccination % (95% CI)
OR
b (95% CI) Effectiveness of
vaccination % (95% CI)
IPD by vaccine types
(c)
Case patients 48 15 (31.3) 0.28
(0.11-0.67)
72% (33-89) 0.23
(0.08-0.60)
77% (40-92)
Control subjects 96 52 (54.2) p = 0.005 p = 0.003
Overall IPD
(d)
Case patients 88 34 (38.6) 0.34
(0.18-0.63)
66% (37-82) 0.28
(0.15-0.54)
72% (46-85)
Control subjects 176 104 (59.1) p = 0.001 p < 0.001
NOTE: OR, odds ratio of vaccination versus no vaccination in cases and controls; Vaccine effectiveness = (1 - matched OR for vaccination)*100%; CI, confidence
interval.
aMantel-Haenszel matched Odds Ratio.
bMatched, adjusted Odds Ratio by conditional logistic regression model.
cAdjusted for age, smoking and stroke.
dAdjusted for age, chronic heart disease, alcoholism and smoking.
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and 76% against vaccine-type infections[19].
Our results differ with those reported in the most
recent meta-analysis by Huss et al, who concluded that
PPV would be not efficacious against either IPD or
pneumonia[17]. However, in the present authors opi-
nion, with regard to IPD this conclusion exceeds the
scope of the evidence from the meta-analysis, given that
pneumococcal bacteraemia was a rare event in the
included RCTs (with only 44 cases of pneumococcal
bacteraemia from 6 studies including 32 770 partici-
pants) and confidence intervals (CI) of vaccine efficacy
were extremely wide[17].
In contrast, our findings fit with those reported in the
latest Cochrane systematic review,[16] which included
10 RCTs involving 35,483 participants assessing this
Table 4 Vaccination histories in cases and control subjects, unadjusted and adjusted Odds Ratios, and estimates of
effectiveness of pneumococcal vaccination against invasive pneumococcal disease according to influenza and
noninfluenza periods.
Unadjusted analysis Adjusted analysis
Type of infection No. of
subjects
No. (%) of
vaccinated
OR
a
(95% CI)
Effectiveness of
vaccination % (95% CI)
OR
b
(95% CI)
Effectiveness of
vaccination % (95% CI)
Within influenza period
(January-April)
(c)
Case patients 50 17 (34.0) 0.30
(0.12-0.73)
70% (27-88) 0.27
(0.08-0.85)
73% (15-92)
Control subjects 100 55 (55.0) p = 0.008 p = 0.025
Within non-influenza period
(May-December)
(d)
Case patients 38 17 (44.7) 0.38
(0.16-0.92)
62% (8-84) 0.37
(0.15-0.92)
63% (8-85)
Control subjects 76 49 (64.5) p = 0.032 p = 0.033
NOTE: OR, odds ratio of vaccination versus no vaccination in cases and controls; CI, confidence interval.
aMantel-Haenszel matched Odds Ratio.
bMatched, adjusted Odds Ratio by conditional logistic regression model.
c Adjusted for age, chronic heart disease and influenza vaccine in the prior Autumn.
d Adjusted for age and diabetes mellitus.
Table 5 Unadjusted and adjusted analyses of vaccination effectiveness against IPD according to age and risk strata of
the patients.
Characteristics of case patients No. of sets No. (% vaccinated) Unadjusted analysis Adjusted analysis
Case patients Control subjects ORa (95% CI) p value ORb (95% CI) p value
Age strata
60-79 yrs 51 17 (33.3) 56 (54.9) 0.36 (0.17-0.78) 0.010 0.32 (0.14-0.74)
d 0.007
80 yrs or more 37 7 (45.9) 48 (64.9) 0.30 (0.10-0.86) 0.026 0.29 (0.09-0.91)
e 0.034
Risk strata
c
Stratum 1 29 11 (37.9) 36 (62.1) 0.31 (0.11-0.89) 0.029 0.12 (0.03-0.53)
f 0.005
Stratum 2 41 18 (43.9) 53 (64.6) 0.32 (0.13-0.79) 0.014 0.29 (0.11-0.79)
g 0.015
Stratum 3 18 5 (27.8) 15 (41.7) 0.48 (0.12-1.91) 0.294 0.40 (0.09-1.89)
h 0.249
NOTE: OR, odds ratio of vaccination versus no vaccination in cases and controls; CI, confidence interval.
aMantel-Haenszel matched Odds Ratio.
bMatched, adjusted Odds Ratio by conditional logistic regression model.
c Among the 29 case patients in risk stratum 1 (possible immunocompromised subjects), main underlying condition for matching was: immunodeficiency in1
case, cancer in 11 cases (4 genitourinary, 3 haematological, 2 lung, 1 digestive, 1 breast), chronic renal disease in 12 cases (10 chronic renal failure, 1 nephrotic
syndrome, 1 dialysis), and corticosteroid therapy in 5 cases. Among the 41 patients in risk stratum 2 (high-risk immunocompetent subjects), main underlying
condition for matching was chronic lung disease in 24 cases, chronic liver disease in 3 cases, chronic heart disease in 8 cases and diabetes mellitus in 6 cases.
Among the 18 patients in risk stratum 3 (non high-risk immunocompetent subjects), 6 were smokers, and they were matched to their controls according to this
condition.
d Adjusted for age, chronic heart disease, smoking and alcoholism.
e Adjusted for age.
f Adjusted for age, stroke and chronic heart disease.
g Adjusted for age, diabetes mellitus, smoking and stroke.
h Adjusted for age and smoking.
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74% (95% CI: 56% to 85%) against all IPD. In the men-
tioned Cochrane review, the pooled vaccine effectiveness
based on 7 observational studies reached 52% (95% CI:
59% to 63%), which is also in agreement with the result
observed in the present study.
Our data is also in agreement with data found in a
prior cohort study among elderly people in the same
geographical area, which pointed to an effectiveness of
40% against overall IPD[28]. Our result also accords
with vaccine effectiveness against IPD reported in the
case-control studies of Shapiro and Clemens (67%),[23]
Sims et al (70%),[24] Farr et al (81%)[25] and Domin-
guez et al (72%)[26].
In the present study, stratified analyses according to
age subgroups showed that vaccination was significantly
effective for all people 60 years or older. We did not
found evidence that vaccination effectiveness decreases
with increasing age considering that in our study vac-
cine effectiveness was 68% (26-86) in people 60-79 years
and it reached 71% (9-91) in people 80 years or more.
According to risk strata of the patients, in our study
the pneumococcal vaccination was significantly effective
in risk strata 1 (immunocompromised subjects) and 2
(immunocompetent subjects with any high-risk condi-
tion). Vaccination did not emerge significantly effective
among the subgroup of patients in risk strata 3 (immu-
nocompetent subjects without high-risk conditions);
however, in order to interpret this result, it must be
noted that our study was clearly underpowered to detect
a possible benefit of vaccination in this subgroup con-
sidering the low vaccine coverage observed among these
patients (27.8%) and the small number of case-control
sets that contributed to this analysis (only 18 sets). Sur-
prisingly, we did not find lower vaccine effectiveness
among immunocompromised people in risk stratum 1.
However, in order to interpret this result, it must be
noted that this stratum included patients with possible
(but not confirmed) immunocompromise and a few
patients assigned to this risk stratum had conditions
associated with severe immunocompromise (see foot-
note in table 5).
A limitation of case-control studies is their observa-
tional nature, which can lead to bias and confounding.
We took care to avoid bias in selection of controls, by
using rigorous methods to select control subjects and
matching cases to controls as closely as possible accord-
ing to the main risk factor and further adjusting for
underlying diseases in the multivariable regression mod-
els. It must be noted that, in our study, case patients
had a significant lower coverage of influenza vaccination
than control subjects, and this could have contributed
to a higher rate of pneumococcal infection among case
subjects. Thus, considering influenza as a possible
confounder, we made stratified analysis on vaccine effec-
tiveness within influenza and noninfluenza periods and
adjusting for influenza vaccine status. Nevertheless, a
residual confounding on the estimates of vaccine effec-
tiveness can not be completely excluded, perhaps
because of undiagnosed illnesses, differences in func-
tional status of the patients or other epidemiological fac-
tors not considered in this study.
The study’sm a j o rs t r e n g t h sw e r et h a ti tw a sp o p u l a -
tion-based, and the study population (people 60 years or
older with and without chronic illness) was representa-
tive and large enough to evaluate the most specific out-
come (IPD due to vaccine serotypes) related with
pneumococcal vaccination in adults. In addition, vaccine
effectiveness was estimated adjusting for important cov-
ariables such as age, underlying conditions and influenza
vaccine status. Thus, although it was not a RCT, it pro-
vides an adequate basis for assessing the potential bene-
fit of the 23-valent PPV in preventing IPD among
people 60 years or older, with and without high-risk
conditions.
Conclusions
Some studies have reported that the PPV is cost-effec-
tive for preventing IPD among people 65 years or older
in the USA and western European countries,[29,30] but
reluctance to use this vaccine exists and current uptakes
are still low in many countries. The benefit of vaccina-
tion for the general elderly and high-risk individuals, as
it has been reported in this study, supports the wide-
spread use of the vaccine. However, it must not be for-
gotten that the vaccine provides incomplete protection,
so the development of more effective vaccination strate-
gies for adults are still necessary. In this way, efforts to
develop new conjugated vaccines with high-serotype
coverage for adults, and investigations into new technol-
ogy protein-based vaccines with potential serotype-inde-
pendent protection against pneumococcal infections are
greatly needed [31,32].
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